Access Vascular Highlights New Midline Catheter Data at AVA 2024
01 Octubre 2024 - 6:07AM
Business Wire
Data Presented at the AVA Annual Scientific
Meeting Shows Significantly Lower Complication and Failure Rates
with Access Vascular’s HydroMID® Midline Catheter
Access Vascular, Inc. (AVI), a leader in tackling critical
vascular access challenges with its advanced hydrophilic
biomaterial technology, today announced findings from a proactive
device evaluation showing a significant reduction in complications
with a midline catheter made with its MIMIX™ hydrophilic
biomaterial (HBM), compared with a conventional coated
catheter.
The evaluation, results of which were shared Sept. 30 at the
annual scientific meeting of the Assn. for Vascular Access,
compared AVI’s HydroMID® device with a polyurethane catheter coated
with chlorhexidine gluconate (CHG).
The HydroMID catheter showed a much lower rate of complications
(5 percent compared with 25 percent for the CHG catheter), despite
longer average dwell times (10.5 days, compared with 8.9 days), and
a 95 percent rate of completion of therapy, compared with less than
80 percent for the control device.
“Our study was prompted by our growing concerns about high
failure and complication rates associated with midline catheters,”
said Stevie Gore, RN, VA-BC, of Montana’s Benefis Health System,
who participated in the study. “Since switching over to the
HydroMID catheter, our patients have benefited from significantly
lower rates of pain and swelling, leakage, superficial vein
thrombosis, dislodgement, occlusion, infiltration, and
fracture.”
Other studies have shown that AVI’s FDA-cleared devices, crafted
from a unique biomaterial that emulates the natural chemistry of
the human body, demonstrated a sixfold reduction in complications
compared to standard catheters, while in vitro data showed a 99.99%
reduction in bacterial adhesion.1,2
About Access Vascular
Access Vascular was founded to address the most common and
costly complications of intravenous therapy: infection, thrombosis,
and phlebitis. Taking a foundationally different approach to
thrombus reduction, the company manufactures intravenous catheters
from a hydrophilic material. Engineered to mimic the body’s natural
chemistry, Access Vascular’s MIMIX®-based catheters are designed to
evade the foreign body response and complications that come with
it. Our award-winning, FDA-cleared products are HydroPICC® and
HydroMID®. For more information, please visit our website, and
follow us on LinkedIn.
____________________
1 Bunch J. A retrospective assessment of
peripheral midline failures focusing on catheter composition. J
InfusNurs. Sept/Oct 2022; 45(5):270-27
2 LeRoy, K. J. 2023 Association for
Vascular Access Scientific Meeting: Poster Abstracts. Journal of
the Association for Vascular Access 1 May 2024; 29 (2): 51–66. doi:
https://doi.org/10.2309/1557-1289-29.2.51
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001644537/en/
Brad Perriello Circle Hill Communications
brad@circlehillcommunications.com 617.817.1385